- Home
- CBAN vs AVIR Comparison
CBAN vs AVIR Comparison
Compare CBAN & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBAN
- AVIR
- Stock Information
- Founded
- CBAN 1975
- AVIR 2012
- Country
- CBAN United States
- AVIR United States
- Employees
- CBAN N/A
- AVIR N/A
- Industry
- CBAN Major Banks
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- CBAN Finance
- AVIR Health Care
- Exchange
- CBAN Nasdaq
- AVIR Nasdaq
- Market Cap
- CBAN 285.4M
- AVIR 273.7M
- IPO Year
- CBAN 1998
- AVIR 2020
- Fundamental
- Price
- CBAN $15.38
- AVIR $2.95
- Analyst Decision
- CBAN
- AVIR Hold
- Analyst Count
- CBAN 0
- AVIR 1
- Target Price
- CBAN N/A
- AVIR $6.00
- AVG Volume (30 Days)
- CBAN 76.0K
- AVIR 410.1K
- Earning Date
- CBAN 04-23-2025
- AVIR 05-13-2025
- Dividend Yield
- CBAN 3.00%
- AVIR N/A
- EPS Growth
- CBAN 14.66
- AVIR N/A
- EPS
- CBAN 1.43
- AVIR N/A
- Revenue
- CBAN $113,756,000.00
- AVIR N/A
- Revenue This Year
- CBAN $14.62
- AVIR N/A
- Revenue Next Year
- CBAN $6.49
- AVIR N/A
- P/E Ratio
- CBAN $10.75
- AVIR N/A
- Revenue Growth
- CBAN 3.33
- AVIR N/A
- 52 Week Low
- CBAN $10.68
- AVIR $2.60
- 52 Week High
- CBAN $18.49
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- CBAN 50.13
- AVIR 48.75
- Support Level
- CBAN $14.54
- AVIR $2.78
- Resistance Level
- CBAN $15.87
- AVIR $2.96
- Average True Range (ATR)
- CBAN 0.63
- AVIR 0.20
- MACD
- CBAN 0.13
- AVIR 0.01
- Stochastic Oscillator
- CBAN 73.94
- AVIR 50.88
About CBAN Colony Bankcorp Inc.
Colony Bankcorp Inc is a bank holding company. The bank provides a broad range of banking services to its retail and commercial customers. Its product line includes loans to small and medium-sized businesses, residential and commercial construction and land development loans, commercial real estate loans, agri-business and production loans, residential mortgage loans, consumer loans, and a variety of demand, savings, and time deposit products. The company's segments include the Banking Division, Retail Mortgage Division and small business specialty lending divisions. It generates maximum revenue from the Banking Division.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).